Hairfollicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hairfolliclestemcells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
A Swiss product called Redensyl, which is supposed to target hairfolliclestemcells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
PP405, a topical LDH inhibitor, has shown to stimulate hairfolliclestemcell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
Microneedling with needle lengths of 1.5mm to 2.5mm to stimulate hairfolliclestemcells for potential hair growth. Using needles longer than 2.5mm is not recommended due to risk of puncturing veins in the scalp. A dermastamp is suggested over a roller.